Morning Song

Dechra Pharmaceuticals (DPH LN) In line trading update & entry to Brazil | Futura Medical (FUM LN) Equity capital raise for MED2002 development | Urban Logistics REIT (SHED LN) Strong NAV performance, and total returns | Zytronic (ZYT LN) Year end update – revenue in line, lower than expected margins

Morning Song

Bagir Group (BAGR LN) Posting of circular and notice of EGM - proposed strategic partnership | Dechra Pharmaceuticals (DPH LN) Sterling progress once again, but one or two clouds on the horizon | Future (FUTR LN) A great summer | Microsaic Systems (MSYS LN) Progressing to plan | Murgitroyd Group (MUR LN) In line trading update, increased dividend, exceptional (historical) item

Morning Song

Craneware (CRW LN) Trading update & contract win | Dechra Pharmaceuticals (DPH LN) In line FY trading update | Eckoh (ECK LN) Contract win through Capita partnership | Miton Group (MGR LN) Strong H1 net inflows, upgrading FY18e EPS by 11% | MySale Group (MYSL LN) Another record year & more potential from platform | Photo-Me International (PHTM LN) On track versus downgraded forecasts. Japan being turned around | Realm Therapeutics (RLM LN) Supportive preclinical data on PR022 vs. tofacitinib in

Morning Song

Dechra Pharmaceuticals (DPH LN) Interims contain no surprises, AST/Le Vet acq now complete | Dialight (DIA LN) Are we nearly there yet? | Eckoh (ECK LN) US secure payments win and new US partnership | GlobalData (DATA LN) Results driven by strong trading | Photo-Me International (PHTM LN) Appointment of CFO | Senior (SNR LN) Solid results and outlook | Sigma Capital Group (SGM LN) REIT placing complete, 140p+/share intrinsic value

Morning Song

Dechra Pharmaceuticals (DPH LN) Acquisition of Le Vet to drive next leg of growth | Low & Bonar (LWB LN) Significant change | PCI-PAL (PCIP LN) Secure payments offers exciting growth potential | Sigma Capital Group (SGM LN) The PRS REIT launches placing programme to raise up to c.£250m

Acquisition of Le Vet to drive next leg of growth

The €340m acquisition of AST Farma/Le Vet looks another superlative deal which is set to drive a period of exceptional growth at Dechra. We upgrade our FY19 EPS forecasts by 10% and by a material 18% in FY20 as the full benefits of the deal begin to be realised. The premium rating is well deserved, and we believe this latest deal puts Dechra on a trajectory towards the FTSE 100 index within a few years. We upgrade to Buy, with a new TP of 2550p.

Morning Song

Dechra Pharmaceuticals (DPH LN) Significant European acquisition | Northern lights The year of the Great Exhibition

Morning Song

1Spatial (SPA LN) US state contract win | Bioquell (BQE LN) Ongoing strength prompts further upgrades | Carr’s Group (CARR LN) Continuing recovery in divisions should help the shares recover | Dechra Pharmaceuticals (DPH LN) Strong, in line H1 update | Gresham Technologies (GHT LN) YE trading update confirms strong progression | IndigoVision Group (IND LN) Pedro Simoes confirmed as new Chief Executive

Strong, in line H1 update

Another strong update from Dechra, leaving the group on track to hit our full year expectations. Growth in North America in particular continues to impress as the group benefits from the increased critical mass from the Putney acquisition, new product registrations and cross-selling opportunities. The more mature European segment remains solid. No change to estimates at this stage, although US tax reform is likely to benefit the bottom line and should lead to useful EPS upgrades at the interims

N+1 Singer - Morning Song 20-10-2017

Dechra Pharmaceuticals (DPH LN) AGM statement confirms all in line | IQE (IQE LN) Unexpected historic US tax bill | PCI-PAL (PCIP LN) Continuing compliance with PCI DSS and new contract win | Renold (RNO LN) Forecasts trimmed to reflect H1 update | SDL (SDL LN) CMD highlights: Technology key to long term competitive advantage

N+1 Singer - Dechra Pharmaceuticals - AGM statement confirms all in line

Dechra’s AGM update confirms all is in line with growth across all business areas. It is still early in the year, but this is reassuring nonetheless. We have been a bit overly cautious with our estimates and are upgrading our EPS forecasts by ~7-8%, bringing us more in line with consensus. The shares now trading on a Cal'17 P/E of 30x, EV/EBITDA of 20x, falling to 27x/17.5x in Cal’18. The FCF Yield is still 4% however so whilst the shares are certainly not cheap, the valuation is not completely

N+1 Singer - T2 Trend spotting - Strategy update

In our second edition of “Trend spotting” we note how in the last three weeks the defensive rotation trend has gathered pace and further evidence has emerged of the “relative fading” in the UK economy. However we now see early signs of the “risk on” trend starting to reassert itself in equity markets and we look at small cap laggards plus European exposure as ways to play this.

N+1 Singer - All creatures great and small - An overview of the animal health sector

Animal Health is a vast market with multiple long-term growth characteristics and opportunities. In this report we have outlined valuations, M&A activity and the key growth drivers in two animal health subsectors: companion animal health and livestock health. Although the commercial positioning of the eight companies covered in this report (Animalcare, Anpario, Benchmark Holdings, CVS Group, Dechra, ECO Animal Health, Genus and Pets at Home) differ significantly, all have exposure to positive ma

Clean exit from ADL Health

EKF has announced a clean solution has been found for the non-core Laboratory Testing business ADL Health, selling the business back to one of its management team. Having pared back our estimates for this division in February, we expect no further material impact on earnings from this move. Strategically, we view it as positive, removing a distraction and further re-focussing activities back towards the core established Point-of-Care & Central Labs business and the growing new Life Sciences acti

SHORE CAPITAL - Destiny Pharma plc+ (DEST, House Stock at 30p)

Hybridan Small Cap Feast - 06 Mar 23

6 March 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objective

LIBERUM: Futura Medical* - Eroxon live in EU, FDA decision now Q2

Hybridan Small Cap Feast - 23 Mar 23

23 March 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv

Positive momentum persists

2022 was a pivotal year for NIOX as it moved firmly into sustainable profitability and cash generation. The foundations for a scalable platform are now well-established and the group enters 2023 with strong momentum (revenues in the first two months of the year were +19%). Having upgraded our forecasts following the trading update in January, we push through further EBITDA upgrades on improved margin assumptions. NIOX is a rare asset and fully deserves a premium rating. We stay at Buy, with an i

Tissue Regenix - FY 2022 – a pivotal year to a sustainably profitable business

Tissue Regenix reported full-year results to 31 December in line with its January trading update that indicated it had reached EBITDA profitability in Q4. What was undisclosed then was that it included a $0.45m provision, without which it would have generated an adjusted EBITDA of c.$0.4m in H2, illustrating the positive underlying progression to a profitable and sustainable growth company. The outlook remains positive – new products, new geographies and additional distributors/strategic partner

Morning Note – 27 March 2023

Hybridan Small Cap Feast - 21 Mar 23

21 March 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv

Morning Note – 21 March 2023

Hybridan Small Cap Feast - 24 Mar 23

24 March 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv

FY22 in line – focus on core increasing

FY22 results are in line with revised estimates. Management continues to intensify its focus on the growing, profitable and cash generative Point-of-Care and Life Sciences activities, where confidence in the latter opportunity is increasing. We make some modest changes to our forecasts to reflect further streamlining post-period end and point to the strong growth outlook from FY24 onwards. We believe this is being overly discounted by the market and view the shares as being in deep value territo

SHORE CAPITAL - Warpaint London+ (W7L, House Stock at 198p)

Destiny Pharma - Positive Phase II data with XF-73 published in medical journal

Destiny Pharma announced the publication of Phase II data with anti-bacterial drug XF-73 nasal gel in the peer-reviewed medical journal, Infection Control & Hospital Epidemiology. The data showed that XF-73 treatment in an 83-patient study resulted in a >99% reduction in nasal Staphylococcus aureus burden (after three applications of nasal gel 24 hours prior to surgery) measured 1 hour prior to cardiac surgery, which was the primary end-point of the study. The data are consistent with previous s

Hybridan Small Cap Feast - 14 Mar 23

14 March 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv